# Rituximab

## Mabthera inj 100mg/10mL

| 藥物代碼           | IMAB1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment, after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                              |
| 副作用             | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting.Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% )Dermatologic: PruritusGastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% )Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% )Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% ) |
| 禁忌               | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation.  Active hepatits B disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 用法用量           | Non-Hodgkin's lymphoma In combination with CVP (cyclophosphamide, vincristine & prednisolone)/CHOP (cyclophosphamide, doxorubicin, prednisone & vincristine) chemotherapy: 375 mg/m2 body surface area for 8 cycles (21 days/cycle), administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of CVP/CHOP. RA IV infusion 1 g followed 2 weeks later by the second 1 g dose. Patients should receive 100 mg IV methylprednisolone 30 mins prior to the infusion.                                                                                                                                                                                                                       |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注意事項           | 1. 第一次使用：給藥速率建議從50 mg/小時開始，之後視病人耐受程度可每30 分鐘提高50 mg/小時，最大速率不可超過 400 mg/小時。 2. 第二次以後使用：給藥速率建議從100 mg/小時開始，之後可每30 分鐘提高100 mg/小時，最大速率不可超過 400 mg/小時。若病人耐受程度良好，快速給藥之給藥時間應 > 60 分鐘。 3. 配製好的輸注溶液濃度約 1 -4 mg/mL，室溫安定性維持 12 小時。 4.患有心律不整、心絞痛、肺疾患的病人， 輸注時加強監測心肺功能。 5. 監測CBC、腎功能。                                                                                                                                                                                                                                                                                      |

## MABTHERA infusion 500mg/50mL

| 藥物代碼           | IMAB5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment, after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                              |
| 副作用             | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting.Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% )Dermatologic: PruritusGastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% )Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% )Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% ) |
| 禁忌               | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation. Active hepatits B disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 用法用量           | Non-Hodgkin's lymphoma In combination with CVP (cyclophosphamide, vincristine & prednisolone)/CHOP (cyclophosphamide, doxorubicin, prednisone & vincristine) chemotherapy: 375 mg/m2 body surface area for 8 cycles (21 days/cycle), administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of CVP/CHOP. RA IV infusion 1 g followed 2 weeks later by the second 1 g dose. Patients should receive 100 mg IV methylprednisolone 30 mins prior to the infusion.                                                                                                                                                                                                                       |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注意事項           | 1. 第一次使用：給藥速率建議從50 mg/小時開始，之後視病人耐受程度可每30 分鐘提高50 mg/小時，最大速率不可超過 400 mg/小時。 2. 第二次以後使用：給藥速率建議從100 mg/小時開始，之後可每30 分鐘提高100 mg/小時，最大速率不可超過 400 mg/小時。若病人耐受程度良好，快速給藥之給藥時間應 > 60 分鐘。 3. 配製好的輸注溶液濃度約 1 -4 mg/mL，室溫安定性維持 12 小時。 4.患有心律不整、心絞痛、肺疾患的病人， 輸注時加強監測心肺功能。 5. 監測CBC、腎功能。                                                                                                                                                                                                                                                                                      |

